Regina Groves joined REVA as Chief Executive Officer in September 2015. Her background encompasses more than 30 years’ experience in medical devices, executive leadership, and financial management. Prior to joining REVA, Ms. Groves served as Vice President and General Manager of the AF Solutions, Cardiac Rhythm and Heart Failure division of Medtronic, a leading global medical technology company. Previously she held positions at Medtronic of Vice President of Quality and Regulatory for the Cardiac Rhythm Disease Management (“CRDM”) business and Vice President and General Manager for Patient Management CRDM. Her experience also includes positions with McKinsey & Company, Inc., several health care companies, including direct providers, and involvement with start-up companies. Ms. Groves received her MBA from Harvard Graduate School of Business Administration and her BS in Pharmacy from the University of Florida. She currently serves on the board of three private companies.
Brandi Roberts was appointed our Chief Financial Officer and Corporate Secretary on August 28, 2017. She brings over 20 years of public accounting and finance experience, including 18 years at publicly traded pharmaceutical, medical technology, and life science companies to her position. Ms. Roberts most recently served as Chief Financial Officer at Mast Therapeutics, Inc., a publicly traded US-based biopharmaceutical company. Additionally, Ms. Roberts held senior positions at Alphatec Spine, Stratagene and Pfizer’s La Jolla Laboratories. She is a certified public accountant and received her B.S. in Business Administration from the University of Arizona and her M.B.A. from the University of San Diego.
Jeffrey Anderson has served as our Senior Vice President of Clinical and Regulatory affairs since December 2013 and as our Vice President of Clinical and Regulatory affairs since February 2011, a position he previously held at REVA from 2004 to 2008. He has over 20 years of experience in the medical device industry, including his positions of Vice President of Clinical & Regulatory Affairs and Vice President of Research & Development for Neomend, a biomedical device company engaged in the development and commercialization of surgical wound healing products, where he served from October 2008 through February 2011. Additionally, Mr. Anderson has held senior positions at Abbott Vascular, Jomed, CRS Clinical Research, and Medtronic. He received his B.S. in Physics from California State University at Fullerton.
Richard Kimes has served as our Senior Vice President of Operations since January 2016. His background comprises over 25 years of operations experience in the medical device industry. Prior to joining REVA, Mr. Kimes held positions of Senior Vice President of Operations for Volcano Corporation and Director of Operations and Process Engineering for Drug-Eluting Stents for Guidant Corporation (now Abbott Laboratories). He also held senior operations positions at mNemoscience GmbH and Elixir Medical Corporation. Mr. Kimes received his B.S. in Mechanical Engineering from the University of Utah.
Carmelo Mastrandrea joined REVA as Vice President, Europe in August 2017. His background encompasses 17 years of experience in sales, with 14 years in the medical device industry, including over ten years in cardiovascular medical devices. Prior to joining REVA, he most recently served as General Manager for Biosensors Europe SA’s business in the D-A-CH region (Germany, Austria, and Switzerland). Previously, he held sales management positions with Biotronik Schweiz AG, and Guidant AG. Mr. Mastrandrea received Swiss Federal diplomas in Machine Engineering from Mitecha Engineering School in Aarau and Business from KV Business School in Basel.
Board of Directors
Mr. Larkin was appointed as a director in July 2017. He currently serves as a principal of Group Outcome L.L.C., a merchant banking firm concentrating on medical technologies. Prior to Group Outcome, Mr. Larkin was Chairman and CEO at Eunoe Inc., an investigative device for slowing and stopping progression of Alzheimer’s disease. From 2001 to 2007, he served as a part-time Venture Partner at Cutlass Capital, a venture capital firm. Prior to that, he was President and Chief Executive Officer of Nellcor Puritan Bennett, Inc., a respiratory products company. Mr. Larkin also held positions of increasing responsibility at Bentley Laboratories/American Hospital Supply from 1976 to 1983. Mr. Larkin currently serves as board chairman of Align Technology, and also served as board chairman of Heartware, Inc. prior to its acquisition by Medtronic, plc. He received his B.S. degree in Industrial Management from LaSalle University and is a former captain in the United States Marine Corps.
Dr. Breckenridge was appointed as a director in January 2015. Dr. Breckenridge is a senior clinical lecturer and Programme Director for the Masters Programme in Clinical and Experimental Medicine at University College London since 2006, a Fellow of the Royal College of Physicians (London) since 2013, and a Consultant Physician at University College London Hospital since 2006. His research focuses on the heart’s response to low levels of oxygen, with an overall aim to identify novel therapeutic targets for cardiac disease. Dr. Breckenridge has provided consultation services to investors in the biotech and healthcare sector since 1998. He is an academic board member of Empower India, and the Cornelia de Lange Society of Great Britain. He obtained his medical degree from Oxford University, followed by his PhD in Developmental Biology at the University of Cambridge and completed his training in Clinical Pharmacology at University College London.
Mr. Dovey has served as a director since June 2001, and was elected Chairman of the Board in March 2016. Since 1988, Mr. Dovey has been a partner of Domain Associates, LLC, a private venture capital management firm focused on life sciences, where he has led innovative investments and has established and directed new initiatives such as the collaboration between Domain and RUSNANO. Since joining Domain, he has served on the board of directors of over 35 private and public companies and has been Chairman of five. He currently sits on the board of two public companies: REVA, and Orexigen Therapeutics. Prior to joining Domain, Mr. Dovey spent six years at Rorer Group, Inc. (now part of Sanofi‑Aventis), a pharmaceutical and medical device company listed on the NYSE. As president of Rorer from 1986 to 1988, he was the primary architect of the company’s strategic shift to pharmaceuticals. Previous to that, he was President of Survival Technology, Inc., a start‑up medical products company. He also held management positions with Howmedica, Inc., Howmet Corporation, and New York Telephone. Mr. Dovey has served as both President and Chairman of the National Venture Capital Association. He is former Chair and currently serves on the Board of Trustees of the Wistar Institute, a non‑profit preclinical biomedical research company. Mr. Dovey serves on the board of directors and is also Chairman at the Center for Venture Education (Kauffman Fellows Program) and on the La Jolla Playhouse Board of Trustees. He was also a former board member of the industry association representing the medical device industry, as well as the association representing consumer pharmaceuticals. He is a trustee emeritus of Germantown Academy and is a former trustee of the University of Pennsylvania School of Nursing and the Burnham Institute for Medical Research. Mr. Dovey received his B.A. in mathematics from Colgate University and his MBA from the Harvard Business School.
Regina Groves joined REVA as Chief Executive Officer in September 2015 and was appointed as a director on June 1, 2017. Her background encompasses more than 30 years’ experience in medical devices, executive leadership, and financial management. Prior to joining REVA, Ms. Groves served as Vice President and General Manager of the AF Solutions, Cardiac Rhythm and Heart Failure division of Medtronic, a leading global medical technology company. Previously she held positions at Medtronic of Vice President of Quality and Regulatory for the Cardiac Rhythm Disease Management (“CRDM”) business and Vice President and General Manager for Patient Management CRDM. Her experience also includes positions with McKinsey & Company, Inc., several health care companies, including direct providers, and involvement with start-up companies. Ms. Groves received her MBA from Harvard Graduate School of Business Administration and her BS in Pharmacy from the University of Florida. She currently serves on the board of three private companies.
Mr. Huennekens was appointed as a director in March 2015. He is currently President and CEO of Verb Surgical, Inc., a collaboration between Alphabet, Inc. (formally Google) and Johnson & Johnson focused on developing a comprehensive robotic surgical solutions platform. Previously, from April 2002 to February 2015, Mr. Huennekens served as President and Chief Executive Officer of Volcano Corporation, a manufacturer of intravascular imaging equipment for coronary and peripheral applications. Prior to 2002, he served as President and Chief Executive Officer of Digirad Corporation, a diagnostic imaging solutions provider, and also held senior positions at Baxter International, Inc. in the Edwards Cardiovascular Division and the Novacor division. Mr. Huennekens currently serves on the boards of EndoChoice and the Medical Device Manufacturers Association (“MDMA”). He received his B.S. in Business Administration from the University of Southern California and an MBA from Harvard Business School.
Dr. Oesterle was appointed as a director in February 2018. He is currently a venture partner at New Enterprise Associates and serves as a Senior Advisor to EQT Partners of Sweden and Temasek Holdings in Singapore. He is also a member of the Board of Directors at Baxter International. Dr. Oesterle was formerly Senior Vice President for Medicine and Technology at Medtronic, Inc. and a member of its Executive Operating Committee for 14 years. He oversaw long term internal technology investments while participating in strategic corporate investments in emerging private companies. Additionally, he served as a member of Medtronic’s Business Development and Strategy Committee that approved all corporate acquisitions. Dr. Oesterle graduated summa cum laude from Harvard and received his M.D. from Yale Medical School; he completed his residency at Massachusetts General Hospital. Following medical school, he completed a fellowship in Interventional Cardiology at Stanford University Hospital. Dr. Oesterle then served on the faculties at Harvard and Stanford medical schools where he directed Invasive Cardiology Services at each hospital.
Mr. Stockman, our co founder, has been a director since 1999, and was our Chairman of the Board from1999 to March 2016. He also served as our Chief Executive Officer from August 2010 to September 18, 2015. He served as a director of HeartWare Limited/HeartWare International, Inc., a NASDAQ-listed medical device company, between December 2006 and July 2016, when the company was acquired by Medtronic. He previously served on the boards of ZELTIQ Aesthetics, Inc., a medical technology company listed on NASDAQ, from July 2010 until April 2012 and MuseAmi, Inc, a privately held advanced music software company that he co-founded. Since 1999, Mr. Stockman has been the President and Chief Executive Officer of Group Outcome LLC, a U.S.-based merchant banking firm that deploys its capital and that of its financial partners in private equity and venture capital investments in medical technology companies. Mr. Stockman also co-founded Centrimed, Inc., an internet-based software company, that was acquired by the Global Healthcare Exchange, LLC, and led the buyouts of Ioptex, an intraocular lens manufacturer, and two Johnson & Johnson divestitures, “A” Company Orthodontics, Inc. and Critikon Company, LLC, each of which was subsequently acquired. Prior to establishing Group Outcome LLC, Mr. Stockman spent 18 years with Johnston Associates, Inc. and Narragansett Capital Corporation, where he focused on venture capital investments and merger advisory work in health care. Mr. Stockman holds a Bachelor’s Degree from Harvard College and an MBA from The Tuck School at Dartmouth College, where he serves on Tuck’s Board of Overseers.
Mr. Thomas has served as a director since July 2010. He has also served as a director and non‑executive Chairman of the Board of HeartWare Limited/HeartWare International, Inc., a NASDAQ-listed medical device company, since November 2004. He is currently a director of a number of Australian public companies, including Virgin Australia Limited and Biotron Limited; he is Chairman of Starpharma Limited. Between October 2004 and September 2008, Mr. Thomas was a consultant to Citigroup Corporate and Investment Bank. Between March 2003 and September 2004, he was Chairman of Global Corporate and Investment Bank, Citigroup Global Markets, Australia and New Zealand. Prior to that time, Mr. Thomas was Chief Executive Officer of Citigroup’s Corporate and Investment Bank (formerly known as Salomon Smith Barney), Australia and New Zealand from October 1999 until February 2003. Mr. Thomas is Chairman of Aus Bio Limited, a director of O’Connell Street Associates and Chairman of Grahger Capital Securities. He also is a member of the advisory board of Inteq Limited. Mr. Thomas holds a Bachelor of Economics from Monash University, Australia. He is a member of the Stockbrokers Association of Australia and is a Master Stockbroker. Mr. Thomas is also a Fellow of the Financial Services Institute of Australia and the Australian Institute of Company Directors. He is on the board of the NSW State Library Foundation and serves on NSW State Library’s Audit and Risk Committee.